|Videos|September 13, 2016

Are We Nearing the End of the Antibiotic Era?

John D'Angelo, MD, senior vice president, executive director of Emergency Medicine Services at Northwell Health, explains why he remains optimistic in the face of antibiotic resistance.

John D'Angelo, MD, senior vice president, executive director of Emergency Medicine Services at Northwell Health, explains why he remains optimistic in the face of antibiotic resistance.

Interview Transcript (slightly modified for readability)

“I think we’re at risk, but the drug industry is very active, as we know, and there [are] always new drugs coming on the market; I’m a little optimistic that we’ll be able to stay ahead of it. The bugs have kind of evolved and they’ve seen our tools and some have adjusted, but I’m hoping we’ll still come out with more ways of attacking the problem, so I’m not worried yet.

I think [that] the innovation that occurs, coupled with better public awareness and better provider practice, not to use antibiotics when they’re not needed, [will help us] get ahead of this.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.